Health and Me

Ishita Roy

Yearly Jab For HIV Protection Is Now Almost Here

Yearly HIV Jab

A new study published in The Lancet medical journal finally found an annual injection designed to prevent Human Immunodeficiency or <span>HIV</span>. This is after the competition of early safety trial. The injectable drug, <span>Lenacapavir</span>, works by stopping the virus from replicating inside cells, potentially offering a long-term alternative to daily medication for HIV prevention.

Currently, individuals at risk of contracting HIV can take pre-exposure prophylaxis (PrEP) in the form of daily pills or injections administered every eight weeks. Lenacapavir, however, could provide protection for an entire year with just a single injection. This would make it the longest-acting form of HIV prevention available if it successfully passes further trials.

PrEP medications are highly effective in reducing the risk of HIV, but adherence to a daily regimen can be challenging for some individuals. A long-lasting injection could help address this issue by making prevention more accessible and convenient.

<h4>The Phase I Trial: A Significant Milestone</h4>

In the initial Phase I trial, 40 HIV-negative participants received an injection of Lenacapavir directly into the muscle. The results showed no major side effects or safety concerns. Additionally, the drug remained detectable in their bodies after 56 weeks, indicating its potential for long-term efficacy.

While these early results are promising, researchers emphasized the need for larger, more diverse clinical trials to further assess the drug’s effectiveness and safety across different populations. These upcoming trials were discussed at the 2025 Conference on Retroviruses and Opportunistic Infections.

<h4>Addressing the Global HIV Epidemic</h4>

According to the latest 2023 figures, approximately 39.9 million people are living with HIV worldwide, with 65% of cases reported in the <span>World Health Organization</span> (WHO) African Region. Global health organizations, including WHO, the Global Fund, and the Joint United Nations Programme on HIV/AIDS (UNAIDS), have set a goal to end the HIV epidemic by 2030. Improving access to preventive measures like PrEP is a key part of this strategy.

<strong>ALSO READ: <a href="https://www.healthandme.com/health-news/japan-could-become-the-first-country-to-eradicate-hiv-article-151242508" data-type="tilCustomLink">Japan Could Become The First Country To Eradicate HIV</a></strong>

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making it more scalable. Researchers believe this innovation has the potential to significantly impact global HIV prevention efforts.

Richard Angell, from the HIV charity Terrence Higgins Trust, called the development of injectable PrEP "exciting and transformational." He highlighted that while daily PrEP pills have already been a game-changer in HIV prevention, a safe, annual injection could further revolutionize the fight against HIV.

However, Angell also pointed out existing inequalities in PrEP access. In many places, oral PrEP is still not available in prisons, online, or through community pharmacies. While Scotland recently approved two-monthly PrEP injections, England is still awaiting approval from the National Institute for Health and Care Excellence (NICE).

Health Conditions A-Z

health

HIV vaccine

lenacapavir

world health organization

health news

CDC To Investigate Link Between Vaccines and Autism, Despite Scientific Consensus

These Are The Five Rare Diseases You Did Not Know Existed

At 28, This Man Is Choosing Euthanasia Over Living With Bipolar Disorder- 'Life Is Absolutely Worth Living But Mine Is Entirely Unbearable'

Health News

10 Upper Body Exercises To Build Arm Strength

10 Foods That Raise Uric Acid Levels

10 Desk Exercises To Keep You Active

10 Exercises To Help You Do Push-Ups Properly

10 Home Exercises For Core Strength

10 Exercises To Help You Relieve Back Pain

10 Low-Sodium Dinner Options You Must Try

10 Health Benefits Of Star Anise

10 Ways To Recover Quickly After Working Out

10 Low-Sodium Healthy Heart Snack

10 Bedtime Habits To Help You Lose Weight

10 Low Carb Lunch Options You Must Try

10 Foods to Avoid Eating During Season

10 Strength Exercises To Help You Burn Belly Fat

10 Food Habits That Are Ruining Your Health

10 Exercises You Should Do For Better Joint Health

10 Foods That Are High-Protein You May Not Know About

10 Fiber Rich Dinner Choices To Try

10 Ways To Curb Unhealthy Cravings

10 Healthy Egg Recipes You Can Try

​10 Morning Exercises You Should Do Everyday​

10 Protein Healthy Bread Recipes

10 Morning Habit You Should Teach Children

10 Nutty Recipes You Should Try For Your Health

10 Exercises You Should Do Before Sleeping

10 Exercises You Should Do For Arm Strength

10 Ways You Can Maximize Your Gym Exercises

10 Exercises You Can Do While Walking

10 Healthy Savoury Pancakes To Have For Breakfast

10 Herbal Tea Mixes For Winters

10 Habits To Ensure Your Teeth Health

10 Detox Juices You Should Try

10 Low Impact Exercises For Weight Loss

10 Foods That Should Be Part Of A Runners Diet

10 Gym Exercises Basketball Players Should Do

10 Light Foods You Can Eat Before Exercises

10 Ways To Beat The Sleep Spell In Office

10 Tips To Help Muscle Recovery

6-6-6 Walking Routine Can Help You Stay Fit

10 Breathing Exercises To Try When You’re Feeling Anxious

A new study published in The Lancet medical journal finally found an annual injection designed to prevent Human Immunodeficiency or HIV. This is after the competition of early safety trial. The injectable drug, Lenacapavir, works by stopping the virus from replicating inside cells, potentially offering a long-term alternative to daily medication for HIV prevention.How Does Lenacapavir Work?Currently, individuals at risk of contracting HIV can take pre-exposure prophylaxis (PrEP) in the form of daily pills or injections administered every eight weeks. Lenacapavir, however, could provide protection for an entire year with just a single injection. This would make it the longest-acting form of HIV prevention available if it successfully passes further trials.PrEP medications are highly effective in reducing the risk of HIV, but adherence to a daily regimen can be challenging for some individuals. A long-lasting injection could help address this issue by making prevention more accessible and convenient.The Phase I Trial: A Significant MilestoneIn the initial Phase I trial, 40 HIV-negative participants received an injection of Lenacapavir directly into the muscle. The results showed no major side effects or safety concerns. Additionally, the drug remained detectable in their bodies after 56 weeks, indicating its potential for long-term efficacy.While these early results are promising, researchers emphasized the need for larger, more diverse clinical trials to further assess the drug’s effectiveness and safety across different populations. These upcoming trials were discussed at the 2025 Conference on Retroviruses and Opportunistic Infections.Addressing the Global HIV EpidemicAccording to the latest 2023 figures, approximately 39.9 million people are living with HIV worldwide, with 65% of cases reported in the World Health Organization (WHO) African Region. Global health organizations, including WHO, the Global Fund, and the Joint United Nations Programme on HIV/AIDS (UNAIDS), have set a goal to end the HIV epidemic by 2030. Improving access to preventive measures like PrEP is a key part of this strategy.ALSO READ: Japan Could Become The First Country To Eradicate HIVA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making it more scalable. Researchers believe this innovation has the potential to significantly impact global HIV prevention efforts.The Need for Equitable AccessRichard Angell, from the HIV charity Terrence Higgins Trust, called the development of injectable PrEP "exciting and transformational." He highlighted that while daily PrEP pills have already been a game-changer in HIV prevention, a safe, annual injection could further revolutionize the fight against HIV.However, Angell also pointed out existing inequalities in PrEP access. In many places, oral PrEP is still not available in prisons, online, or through community pharmacies. While Scotland recently approved two-monthly PrEP injections, England is still awaiting approval from the National Institute for Health and Care Excellence (NICE).